Tarsus Pharmaceuticals, Inc. (TARS)

NMS – Real Time Price. Currency in USD

59.83

+0.18 (0.30%)

At close: May 12, 2026, 4:00 PM EDT

59.83

0.00 (0.00%)

After-hours: May 12, 2026, 5:13 PM EDT

07.05.2026

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

07.05.2026

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

06.05.2026

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.64 per share a year ago.

06.05.2026

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026 , at 1:30 p.m. PT / 4:30 p.m.

29.04.2026

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.

14.04.2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis, with early signs of payoff seen, as sales now exceed SG&A expense. The company has appointed star biotech executive David Pyott, former CEO and Chairman of Allergan Inc, to the Board. TARS has H1'27 clinical catalysts from trials of lotilaner in Lyme-disease prevention/tick-killing and ocular rosacea.

31.03.2026

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

31.03.2026

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

23.03.2026

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China.

18.02.2026

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors.

Tarsus Pharmaceuticals, Inc. (TARS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Videos

No Data

Press releases

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Videos

No Data

Press releases

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Search stocks

Tarsus Pharmaceuticals, Inc. (TARS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Videos

No Data

Press releases

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Videos

No Data

Press releases

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors